Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianxin Lin

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Nanoscale|February 27, 2020
YBa<sub>2</sub>Cu<sub>3</sub>O<sub>7</sub> nano superconducting quantum interference devices on MgO bicrystal substratesJianxin Lin, Benedikt Müller, Julian Linek, et al.
Nanomaterials (Basel, Switzerland)|August 27, 2025
Interstitial Ag<sup>+</sup> Engineering Enables Superior Resistive Switching in Quasi-2D Halide PerovskitesHaiyang Qin, Zijia Wang, Qinrao Li, et al.
Biostatistics (Oxford, England)|June 19, 2018
Bayesian inference for network meta-regression using multivariate random effects with applications to cholesterol lowering drugsHao Li, Ming-Hui Chen, Joseph G Ibrahim, et al.
The American Journal of Cardiology|January 27, 2009
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapyThomas A Pearson, Christie M Ballantyne, Enrico Veltri, et al.
Atherosclerosis|October 9, 2012
Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patientsNuntakorn Thongtang, Jianxin Lin, Ernst J Schaefer, et al.
Lipids in Health and Disease|September 5, 2015
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease riskJeffrey B Rosen, Christie M Ballantyne, Willa A Hsueh, et al.
Journal of Clinical Lipidology|February 5, 2011
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive proteinMichael H Davidson, Nicola Abate, Christie M Ballantyne, et al.
Atherosclerosis|April 28, 2015
Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patientsOlivier Descamps, Joanne E Tomassini, Jianxin Lin, et al.
Chemical Communications (Cambridge, England)|June 22, 2022
Enhanced ammonia synthesis activity of carbon-supported Mo catalyst by Mo carburizationBiyun Fang, Chuanfeng Zhang, Jiahui Li, et al.
ACS Applied Materials & Interfaces|November 28, 2023
Boosting N<sub>2</sub> Conversion into NH<sub>3</sub> over Ru Catalysts via Modulating the Ru-Promoter InterfaceKailin Su, Dongya Huang, Hongpeng Fang, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Nanoscale|February 27, 2020
YBa<sub>2</sub>Cu<sub>3</sub>O<sub>7</sub> nano superconducting quantum interference devices on MgO bicrystal substratesJianxin Lin, Benedikt Müller, Julian Linek, et al.
Nanomaterials (Basel, Switzerland)|August 27, 2025
Interstitial Ag<sup>+</sup> Engineering Enables Superior Resistive Switching in Quasi-2D Halide PerovskitesHaiyang Qin, Zijia Wang, Qinrao Li, et al.
Biostatistics (Oxford, England)|June 19, 2018
Bayesian inference for network meta-regression using multivariate random effects with applications to cholesterol lowering drugsHao Li, Ming-Hui Chen, Joseph G Ibrahim, et al.
The American Journal of Cardiology|January 27, 2009
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapyThomas A Pearson, Christie M Ballantyne, Enrico Veltri, et al.
Atherosclerosis|October 9, 2012
Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patientsNuntakorn Thongtang, Jianxin Lin, Ernst J Schaefer, et al.
Lipids in Health and Disease|September 5, 2015
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease riskJeffrey B Rosen, Christie M Ballantyne, Willa A Hsueh, et al.
Journal of Clinical Lipidology|February 5, 2011
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive proteinMichael H Davidson, Nicola Abate, Christie M Ballantyne, et al.
Atherosclerosis|April 28, 2015
Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patientsOlivier Descamps, Joanne E Tomassini, Jianxin Lin, et al.
Chemical Communications (Cambridge, England)|June 22, 2022
Enhanced ammonia synthesis activity of carbon-supported Mo catalyst by Mo carburizationBiyun Fang, Chuanfeng Zhang, Jiahui Li, et al.
ACS Applied Materials & Interfaces|November 28, 2023
Boosting N<sub>2</sub> Conversion into NH<sub>3</sub> over Ru Catalysts via Modulating the Ru-Promoter InterfaceKailin Su, Dongya Huang, Hongpeng Fang, et al.
Pageof 9